Healthcare / Drug Manufacturers - Specialty & GenericNSE
$14.77
-0.59 (-3.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-101.1M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
64/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.9B
P/E
20.2x
↓EV/EBITDA
19.5x
↑ROE
14.4%
↑Gross Margin
31.0%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.1%
FCF CAGR
+39.0%
FCF margin
2.9%
FCF / Net income
0.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.57B · net income $494.3M · FCF $134.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.57B | $4.57B | $2.59B | $2.22B | $2.18B |
| Net Income | $494.3M | $494.3M | $253.1M | $200.7M | $197.9M |
| EBITDA | $714.2M | $714.2M | $430.3M | $343.0M | $319.5M |
| EPS | 0.53 | 0.53 | 0.27 | 0.22 | 0.24 |
| Gross Margin | 31.0% | 31.0% | 36.4% | 32.6% | 32.6% |
| Operating Margin | 11.8% | 11.8% | 9.7% | 7.4% | 7.9% |
| Net Margin | 10.8% | 10.8% | 9.8% | 9.0% | 9.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.25 | 0.32 | 0.26 |
| Current Ratio | 3.19 | 3.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $134.8M | $134.8M | $-140.9M | $-101.1M | $50.2M |
| Returns | |||||
| ROE | 14.4% | 14.4% | 8.8% | 7.8% | 8.9% |
| Valuation | |||||
| P/E | 20.23 | 20.23 | 50.50 | 30.30 | — |
| EV/EBITDA | 19.50 | 19.50 | 29.92 | 20.13 | — |
| P/B | 4.06 | 4.06 | 4.44 | 2.38 | — |
| Growth & Yield | |||||
| Revenue Growth | 76.4% | 76.4% | 16.5% | 2.1% | — |
| EPS Growth | 95.3% | 95.3% | 24.6% | -9.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
35.6%
EPS terminal req.
$1.31
Spread vs growth
59.7%
5Y implied EPS CAGR
24.7%
EPS terminal req.
$1.59
Spread vs growth
70.6%
10Y implied EPS CAGR
17.1%
EPS terminal req.
$2.55
Spread vs growth
78.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.0%
Start / end P/E
82.0x → 28.5x
EPS bridge
0.27 → 0.53
Residual
-62.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.